scientific image. Text: "Chaos in lymph nodes promotes cancer"

In aggressive #lymphomas, inflammatory messengers reprogram the ​“conductors” of the immune system, causing lymph node structure to collapse. A team led by @simonhaas.bsky.social describes this process in ​“Nature Cancer” using #singlecell and spatial analyses: www.mdc-berlin.de/news/press/c...

Another great poster @TheUSCAP today: "Immunostaining of Mediastinal Grey Zone #Lymphomas for CD48 and LMO2 Shows a Mixed Pattern Skewed to Classic Hodgkin Lymphoma" by Drs. Georgi Lukose, Ivo Sah Bandar, Megan Kachin, Mandela Bilal, Isabella Kong, Lisa Giulino Roth, Ethel Cesarman & Amy Chadburn!

VIH, hepatites e cancro foram áreas distinguidas nos Prémios Gilead Génese Já são conhecidos os premiados da edição deste ano dos Prémios Gilead Génese, programa que apoia iniciativas e investigação na área da saúde. Foram distinguidas 10 iniciativas. O investimento total ul...

Delfim Duarte, group leader at #i3S, studies immunotherapies in aggressive #lymphomas. His work was recognized by the Gilead Genesis program, which awarded 37 500€ to study the role of blood vessels responsible for recruiting immune cells that fight lymphoma

Congratulations👏

#i3Sawards #i3Snews

📣ESMO #ClinicalPracticeGuideline on #Lymphomas - New Living Guideline recommendations in the relapsed/refractory setting:
- Epcoritamab combinations and odronextamab in Follicular Lymphoma
- Sonrotoclax in Mantle Cell Lymphoma thrid-line or later

🔗 https://ow.ly/v7Uo50YcbSE

Challenges in PTCL Management Identified in Asia Researchers identified several diagnostic and treatment challenges for patients with PTCLs in Asia.

Diagnostic and treatment challenges for peripheral T-cell #lymphomas were identified, and potential solutions discussed at the Singapore Scientific Symposium 2024 by a panel of #lymphoma experts from across Asia. From @ascopost.bsky.social journal JCO Global Oncology.

https://bit.ly/3Nd3PDd

#lymsm

FT516, an engineered, off-the-shelf NK cell product derived from induced pluripotent stem cells, demonstrated meaningful clinical activity in patients with R/R B-cell #lymphomas in a phase I trial, with an ORR of 58%, along with a favorable safety profile: https://ow.ly/7AMq50XqMof
#HemeSky #OncSky

Implant Implications: In addition to #anaplastic large-cell #lymphomas (ALCL), breast implants following #mastectomy may be linked to other lymphomas. A study of 61,000+ women found five cases of #DLBCL, two of SLL, and one of peripheral #Tcell lymphoma, plus seven cases of ALCL.
#HemeSky #OncSky

📣 New ESMO #Lymphomas Living Guideline v1.0.
Includes all recommendations and algorithms from the published #ClinicalPracticeGuideline, covering major lymphoma subtypes in an interactive format.

🔗 https://ow.ly/wLFE50X7y9e

#ESMOGuidelines

Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† The treatment landscape for many lymphoma entities continues to evolve rapidly, with multiple recent approvals of novel non-chemotherapy (ChT)-based approaches. The following Clinical Practice Guideli...

Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† - Annals of Oncology www.annalsofoncology.org/article/S092...
#HematoSky #Lymphomas

📣 New ESMO #ClinicalPracticeGuideline on #lymphomas: evidence-based recommendations for all major #lymphoma subtypes, updated as needed as an ESMO Living Guideline, reflecting developments in Tx.
#DLBCL #PCNSL #FollicularLymphoma #HodgkinLymphoma #ESMOGuidelines

🔗 buff.ly/2ZYJc2c

In the adjuvant setting, vaccines against melanoma and pancreatic cancer appear to be reducing minimal residual disease and relapse. In the #macrometastatic setting, in-situ vaccines have induced systemic regressions in advanced-stage #lungcancers & #breastcancers & #lymphomas

I'm just this guy you don't know. I love you in a totally not creepy way unless you specifically ask for that. Need to try & sleep! #Thankful #lymphomas

📣 Updated ESMO-EHA #ClinicalPracticeGuideline on management of ‘mature’ or ‘peripheral’ T- and NK-cell #lymphomas: 👉 clinical features, histopathological diagnosis, imaging, staging and risk assessment, treatment and follow-up.
🔗 buff.ly/dvDOsNK
@hemasphere-journal.bsky.social #ESMOGuidelines

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) — Recursion NASDAQ:RXRX, a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first pati...

#RXRX
#Recursion Announces First Patient Dosed in Phase 1 Clinical Study of #REC-3565, a Selective #MALT1 Inhibitor for #Relapsed or #Refractory #B-cell #Lymphomas

www.tradingview.com/news/reuters...

Research Alert: Managing Blood Cancers During Pregnancy – Expert Guidance | Newswise Experts from RWJBarnabas Health and Rutgers Cancer Institute, New Jersey’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, recently published a review examining the challe...

Research Alert: Managing Blood Cancers During Pregnancy – Expert Guidance
www.newswise.com/articles/res...
#leukemia #Lymphomas #chemotherapy #pregnancy #TargetedTherapies #immunotherapy

Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England The distribution of trial site locations may lead to disparities in geographic access and affect patient representativeness in clinical trials. We utilised trial data covering 1993–2022 from the Nati...

NEW PUBLICATION

Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England

#clinicaltrials #epidemiology #lymphomas #geographicbarriers #inequalities

onlinelibrary.wiley.com/doi/10.1111/...

@oxpop.bsky.social

Our lab at is #hiring! Open #postdoc position for a mixed dry-wet lab to leverage multi-omic techniques to determine biomarkers of response and resistance B-cell #lymphomas treated with #CAR-T therapy. Deadline 26th February. Reach out if interested or kindly share.
qmul-jobs.tal.net/vx/mobile-0/...

Lurie Cancer Center’s Leo Gordon, MD (@ligordon.bsky.social), Vice-Chair of the NCCN Clinical Guidelines for B-Cell #Lymphomas discusses critical 2024 guideline changes with OncLive www.onclive.com/view/vice-ch... #lymsm

The behaviour of therapeutic antibodies in immunotherapy | CNRS Non-Hodgkin lymphomas are among the most common cancers affecting almost 1.5 million people globally. They cause uncontrolled proliferation of B lymphocytes, a type of white blood cell, to the detriment of healthy cells. Since the end of the 1990s, immunotherapy had been a frontline treatment using synthetic antibodies to target a protein on the surface of B lymphocytes called CD20. The body’s defences then identify these cells covered in antibodies as pathogens and destroy them.

The Behavior of Therapeutic Antibodies in #Immunotherapy:#cancer #NonHodgkin #lymphomas

cnrs.fr/en/behaviour-t…